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Abstract 
The last two decades have witnessed a revolution in the treatment of autoimmune 
diseases due to the introduction of biological agents which, although now included as 
standard treatment in patients with autoimmune rheumatological, dermatological and 
gastrointestinal diseases. The use of biological agents is associated with greater costs 
compared with the mainly anti-inflammatory and immunosuppressant drugs used in the 
pre-biological era. Biosimilars are highly similar copies of biological drugs, but not 
identical to approved ‘reference’ agents. Biological agents are complex proteins 
involved in the immune response and their exact replicas are extremely difficult, if not 
impossible, to obtain. Three scenarios have converged to provide a specific 
opportunity for biosimilars in autoimmune diseases: growing demand for biologics due 
to successful clinical use; the nearing of patent expiry for the four top-selling biological 
brands; and the search to reduce health costs due to the financial crisis. We aimed to 
review the crucial topics of efficacy, safety and regulatory approach of upcoming 
biosimilars. 
 
1. Introduction 
The last two decades have witnessed a revolution in the treatment of autoimmune diseases due to the introduction of 
biological agents which, although now included as standard treatment in patients with autoimmune rheumatological, 
dermatological and gastrointestinal diseases, are associated with greater costs compared with the mainly anti-
inflammatory and immunosuppressant drugs used in the pre-biological era. Biotechnological advances have resulted in 
the “generic” versions of biologicals, known as biosimilars. The term biosimilar was first used in Pubmed in 2004 [1]. 
Since then, 7 biosimilar products sold under 13 different names have been licensed in Europe: two human growth 
hormones (somatropin), three granulocyte-colony stimulating factors (filgrastim), and two erythropoietins that have 
received different international nonproprietary names, [epoetin-alfa (HX-575) and epoetin-zeta (SB-309)] [2]. 
Three scenarios have converged to provide a specific opportunity for biosimilars in autoimmune diseases: growing 
demand for biologics due to successful clinical use; the nearing of patent expiry for the four top-selling biological 
brands; and the search to reduce health costs due to the financial crisis. 
The rapid expansion of the biosimilar market is attracting a swarm of pharmaceutical and biotechnology companies to a 
market estimated at US$2 billion in the USA alone in 2012 and a projected rise to nearly $20 billion by 
2018 [3] and [4]. However, physicians may view this as something of a biotechnical bubble, far from the reality of 
clinical practice as, until now, there is no solid scientific evidence supporting the use of biosimilars in autoimmune 
diseases. The doubts expressed about the safe, efficacious use of biosimilars seem to augment rather than diminish. 
Biosimilars are copies of biological agents, which are complex proteins involved in the immune response 
[overwhelmingly monoclonal antibodies (mAbs)]. Biologicals are a complex collection of large protein isoforms with 
two crucial functional features: affinity and selectivity, which are highly dependent on post-translational events such as 
glycosylation[5] and [6]. All alterations result in significant functional variations and, therefore, exact replicas of mAbs 
are extremely difficult, if not impossible, to obtain [7]. Physiochemical and biological methods of characterizing mAbs 
are increasingly sophisticated, but comparison of biosimilars to the reference biologic remains difficult. Biosimilar 
development requires significant investment, technical capability and clinical trial expertise, with estimated average 
costs of $200–250 million [8]. 
Biosimilars are not generic drugs and their licensing requires a different regulatory approach. Europe was the first 
region to establish specific regulatory approval processes for biosimilars, based on scientific data and maintaining the 
stringent standards required for the original biologic. The Biosimilar Medicinal Products Working Party (BMWP) of the 
European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) has launched various 
guidelines and rules for the use of biosimilars containing biotechnology-derived proteins (572643/2011 and 
572828/2011), with an updated review discussing and accepting external amendments. The EMA guidelines on 
biosimilars based on mAbs (632613/2009 and 403543/2010) clearly differentiate between those with cytotoxic 
mechanisms of actions (mainly anti-cancer mAbs) and immunomodulatory mAbs (overwhelmingly used in autoimmune 
diseases). The main objective is to establish non-clinical and clinical requirements to guide applicants for standardized 
development programs. The USA lags somewhat behind Europe in this field, since the Food and Drug Administration 
(FDA) has not yet issued a specific regulatory pathway similar to the EMA proposal. The Biologics Price Competition 
and Innovation (BCPI) Act outlined shortened approval processes for “highly similar” biologic products, enabling 
evaluation of biosimilars against a single, already-licensed, reference biologic therapy [9]. In February 2012, the FDA 
issued draft industry guidance on implementation of the BPCI Act approval process. 
The World Health Organization (WHO) also provided norms and standards for the evaluation of these products in 
2009 [10]. Written standards established through the Expert Committee on Biological Standardization at the WHO 
(ECBS) may serve as a basis for setting national requirements for production, quality control and overall regulation of 
biological medicines. These norms require documentation of the manufacturing process, preclinical physiochemical 
studies, toxicity study in animals, clinical pharmokinetic studies comparing the biosimilar product to the original 
biological, phase III clinical efficacy studies, immunogenicity studies in humans, and an appropriated 
pharmacovigilance plan. 
However, controversy is anticipated with interests supporting or opposing the biosimilar approval pathway [11]. 
Some government agencies in Asia (e.g. Japan, Malaysia, Singapore, South Korea, Sri Lanka and Taiwan) have 
established their own regulatory pathways for the evaluation and approval of biosimilar agents, which may differ from 
EMEA and FDA positions. 
At present, China is developing regulations that specify requirements for the evaluation and approval of biosimilars 
based on the WHO guidance, although biosimilar agents to treat patients with rheumatic diseases are already 
commercialized [12]. 
Efforts are centered mainly on developing biosimilars for the four most-frequently used biological agents, whose 
patents expire in the next few years (Table 1). 
 
 
2. Rituximab 
The development of rituximab biosimilars is ongoing. Reditux®, a rituximab copy manufactured by India-based generic 
drug manufacturer, Dr Reddy's Laboratories, was the first intended copy of mAb launched, being introduced in India in 
April 2007 at 50% of the original price. Likewise, Kikuzubam® is manufactured by the Mexican firm, Probiomed, and 
is used in Mexico, Bolivia, Peru and Chile. Several companies are conducting phase I and II studies of rituximab 
biosimilars in rheumatoid arthritis (Table 1). The completion of Boehringer Ingelheim's phase III trial of its rituximab 
biosimilar (BI 695500) is expected in April 2015. However, recent communications have cast a shadow on the 
extremely-rapid, seemingly-promising development of biosimilars. In October 2012, Teva suspended plans for a phase 
III clinical trial of its rituximab biosimilar in rheumatoid arthritis, while Samsung Electronics has also temporarily 
ceased clinical development of its biosimilar [13]. Exact reasons were not given in either case, but it would be 
interesting to know whether economic and/or technical reasons were involved. 
3. Infliximab and adalimumab 
In February 2012, Celltrion announced the successful completion of a clinical program of its infliximab biosimilar, 
Remsima® (CT-P13) including 874 patients with active rheumatoid arthritis (257 patients in phase I; 617 patients in 
phase III) from 100 hospitals in 19 countries. The 30-week phase III trial measuring American College of 
Rheumatology 20% improvement criteria (ACR20) had response rates of 73% with Remsima® and 70% with original 
infliximab, and found no significant pharmacokinetic differences between the biosimilar and the original [14]. 
Infection-related adverse advents were reported in 46 (15%) and 51 (17%) patients in the CT-P13 and infliximab arms, 
respectively, and tuberculosis in 3 and 1 patients, respectively. 
Preliminary positive results of a phase I randomized controlled trial in 250 ankylosing spondylitis patients were 
presented at the last EULAR meeting [15]. 
In late July 2012, the Korean Food and Drug Administration (KFDA) approved Remsima® for use in RA, Crohn's 
disease, ulcerative colitis, ankylosing spondylitis, and psoriatic arthritis. The price is 30% lower than the current 
original Infliximab price and it is already commercially available. According to the September 2012 EMA list of 
applications for new human medicines under CHMP evaluation, two applications for biosimilar versions of infliximab 
will be reviewed. Adalimumab will lose patent protection in the USA, Japan and European Union in 2016, 2017 and 
2018, respectively, and companies are working to develop adalimumab-based biosimilars for the same indication of the 
original biological. 
4. Etanercept 
In October 2009, the Taiwan-based Mycenax announced its etanercept biosimilar, TuNEX®, had successfully 
completed phase I trials in 23 healthy Korean male volunteers[16]. A Taiwanese phase III study is underway and 
Mycenax is seeking partners for its introduction in other markets. Other etanercept intended copies are currently 
marketed in China (Yisaipu) and Colombia (Etanar), and the HD203 compound is under evaluation in Korean RA 
patients [17]. 
5. Immunogenecity 
The number and diversity of reported autoimmune diseases triggered by biological agents has increased in parallel with 
their increasing use [18] and [19]. Biological agents have been related with the development of advert events including 
autoimmune process [20]and physicians should bear this in mind when biosimilars are postulated as therapies for 
autoimmune diseases. Impurities in biological products, structural modifications resulting from the manufacturing 
and/or suboptimal storage conditions can increase the risk of immunogenicity, leading to the possible production of 
antibodies against any biosimilar component [21]. Human anti-monoclonal antibodies (HAMAs) may bind to and 
attenuate or inactivate the biosimilar, resulting in hypersensitivity reactions such as allergy or serum sickness, or even 
unexpected autoimmune effects. This was reported in 2002, when some patients treated with a recombinant 
erythropoietin developed autoimmune-related pure red-cell anemia [22] and [23]. 
6. Current and future perspectives 
Currently, there is a startling disconnect between the development of biosimilars and the scarcity of scientific 
information on their safety and efficacy in patients with autoimmune diseases. For example, at the 2012 European 
League Against Rheumatism (EULAR) and ACR meetings, only two abstracts on the use of biosimilars in autoimmune 
diseases were presented [14] and [15]. Physicians probably know the concept and potential cost-benefits but require 
further evidence before accepting that biosimilars are effective, safe, cheaper options to biologics. The outlook is further 
complicated by the fact that the regulatory rules for biosimilars are at very-different stages in the US, European 
and pharmemergingmarkets and even vary by country. 
Transparency regarding the results of ongoing trials (especially with respect to emerging safety issues) and involvement 
in the planning and conduct of future trials and regulatory rules is required. Feedback on the EMA draft guidelines 
mainly comes from representatives of regulatory agencies, pharmaceutical companies and patient organizations, but not 
from any national or European medical associations. As stated by Ebbers et al. [24], “when regulators fail to involve 
doctors in their activities, this will impede the acceptance of the cost-effective and innovative medicinal products of the 
future.” Greater engagement between regulatory authorities, pharmaceutical companies and the medical community 
would be welcome to be sure that the full process, from synthesis to manufacturing meets the highest standard to 
guarantee efficacy and safety. The potential save in cost related to biosimilar use should not have an impact in the 
outcome of our patients. 
Take-home messages 
• Biological agents represent a revolution in the treatment of autoimmune diseases. 
• Biosimilars are not “generic” of biological agents as biological cannot be copied. 
• Biosimilars' license requires a different regulatory approach from generic ones. 
• Biosimilar may represent a potential save in cost. 
• The highest standards in manufacturing are required to guarantee efficacy and safety. 
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Table 1. 
Pipeline for development of biosimilars in autoimmune diseases. 
Drug Correspondent 
biological 
Manufacturer 
(location) 
Primary outcome measures 
Preclinical trails    
 Avent™a Etanercept Avesthagen (India) Efficacy and toxicity 
 PRX-106b Etanercept Protalix 
Biotherapeutics 
(Israel)a 
Efficacy and toxicity 
Clinical trials 
(phase/statec) 
   
 BI695501 
(I/completed)c 
Adalimumab Boehringer Ingelheim 
Pharmaceuticals 
(Germany) 
– Area under the concentration-time 
curve of the analyte in plasma over the 
time interval from 0 extrapolated to 
infinity [Time Frame: 72 days] 
– Maximum measured concentration 
of the analyte in plasma [Time Frame: 
72 days] 
 LBEC0101 
(I/completed)c 
Etanercept LG Life Sciences Ltd. 
(South Korea) 
Etanercept levels in blood [time 
frame: 22 day] 
 CT-P10 (I in 
AR/recruiting)c 
Rituximab Celltrion (South 
Korea) 
Compare pharmacokinetics in terms 
of Cmax [time frame: up to week 24] 
 PF-05280586 (I 
and II in 
AR/recruiting)c 
Rituximab Pfizer (US) Pharmacokinetic parameter Cmax [time 
frame: week 25] 
Pharmacokinetic parameter AUC 0-∞ 
[Time Frame: Week 25] 
 GP2013 (I and II in 
AR/recruiting)c 
Rituximab Sandoz 
Biopharmaceuticals 
(Switzerland) 
Compare pharmacokinetics of GP2013 
and rituximab following IV infusion in 
patients with RA [time frame: 
24 weeks] 
 TL011 (I and II in 
AR/completed)c 
Rituximab Teva Pharmaceutical 
Industries (Israel) 
Compare pharmacokinetics of 
rituximab following IV infusions of 
TL011 and MabThera® in subjects 
with RA 
 HD203 (I and III in 
AR/completed; 
Active, not 
recruiting)c 
Etanercept Hanwha Chemical 
(South Korea) 
Etanercept levels in blood [time 
frame: 21 days] 
– To prove the equivalence between 
two groups by comparing the ACR20 
of W24 with the baseline after 
injecting HD203 and Enbrel® into 
rheumatoid arthritis patients for 
24 weeks 
 TuNEX (III)c Etanercept Mycenax Biotech 
(Taiwan) 
The primary efficacy endpoint is 
defined as ACR20 responder at last 
treatment visit (Week 24). 
Drug Correspondent 
biological 
Manufacturer 
(location) 
Primary outcome measures 
 CT-P13 (I in AS 
and III in AR/active, 
not recruiting)c 
Infliximab Celltrion (South 
Korea) 
Long term efficacy evaluated by 
American College of Rheumatology 
(ACR) criteria and Long term safety 
evaluated by immunogenicity and 
clinical laboratory test [time frame: up 
to week 40] 
Marketed (location)    
 Yisaipu (China) Etanercept Shanghai CP Goujian 
Pharmaceutical Co. 
(China) 
 
 Etanar® 
(Colombia) 
Etanercept Shanghai CP Goujian 
Pharmaceutical Co. 
(China) 
 
 Reditux® (Bolivia, 
Chile, India and 
Peru) 
Rituximab Dr Reddy's 
Laboratories (India) 
 
 Kikuzubam® 
(Bolivia, Chile, 
Mexico, and Peru) 
Rituximab Probiomed (Mexico)  
Development or 
pipeline 
   
 Development Adalimumab, 
rituximab 
BioXpress 
Therapeutics S. A. 
(Switzerland) 
 
 Pipeline Abatacept, 
Etanercept, 
Golimumab, 
Infliximab, 
Tocilizumab 
BioXpress 
Therapeutics S. A. 
(Switzerland) 
 
AS: ankylosing spondylitis; AR: rheumatoid arthritis. 
a http://www.avesthagen.com/docs/020910pr.pdf 
b http://www.protalix.com/index.asp. 
c Data from clinicaltrails.gov at February 2013. 
 
